All News

Found 61 articles

• Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

  10/21/2021

  Ultimovacs ASA announced its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab.

• 

  Clinical Catch-Up: October 11-15

  10/18/2021

  It was yet another busy week for clinical trial announcements. Take a look.

• Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

  10/13/2021

  Ultimovacs ASA announced continuing positive topline results in its ongoing U.S.-based Phase I clinical trial evaluating the Company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma.

• 

  Clinical Catch-Up: September 27-October 1

  10/4/2021

  It was a busy week for clinical trial news. Here’s a look.

• Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

  10/1/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced it has started dosing of the second cohort in the Phase I TENDU trial, evaluating the Company's Tetanus-Epitope Targeting -platform.

• Ultimovacs ASA: Second Quarter 2021 Result Presentation

  8/20/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2021 results.

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.

• Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma

  8/12/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced positive topline results from the second cohort of 10 patients after one year of its ongoing U.S.-based Phase I clinical trial evaluating the Company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma.

• Ultimovacs ASA: Invitation to Second Quarter 2021 Results Webcast Presentation

  8/11/2021

  Ultimovacs ASA invites to a webcast presentation of its second quarter 2021 results on Friday 20 August 2021.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Ultimovacs Announces First Patient Enrolled in Phase II FOCUS Trial of UV1 in Head-and-Neck Cancer

  8/5/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in FOCUS, an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the Company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab.

• Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

  7/5/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Company’s universal cancer vaccine, UV1.

• 

  Clinical Catch-Up: June 1-6

  6/7/2021

  With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.

• Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

  6/4/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), announced that data on its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

• Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

  6/1/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that a peer-reviewed article on the ongoing NIPU Phase II trial of the Company’s universal cancer vaccine, UV1, in malignant pleural mesothelioma (MPM) has been published

• Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

  5/19/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate in metastatic malignant melanoma.

• Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

  5/11/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company’s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma

• Ultimovacs ASA: First Quarter 2021 Result Presentation

  5/11/2021

  Ultimovacs ASA, a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results

• Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings

  5/10/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team will discuss data from the abstract of a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting at a series of investor events in May, beginning with a live corporate webcast on Thursday May 20, 2021.

• Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting

  4/28/2021

  Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company’s Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting